Synergy Pharmaceuticals Inc  

(Public, NASDAQ:SGYP)   Watch this stock  
Find more results for OTC:SGYP
-0.02 (-0.56%)
Real-time:   2:40PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.38 - 3.55
52 week 2.50 - 10.15
Open 3.52
Vol / Avg. 1.91M/4.77M
Mkt cap 636.40M
P/E     -
Div/yield     -
EPS -1.35
Shares 179.78M
Beta 1.52
Inst. own 36%
Aug 8, 2016
Q2 2016 Synergy Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
May 10, 2016
Q1 2016 Synergy Pharmaceuticals Inc Earnings Release
May 4, 2016
Synergy Pharmaceuticals Inc at Deutsche Bank Health Care Conference
Mar 14, 2016
Synergy Pharmaceuticals Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -235.34% -74.15%
Return on average equity - -
Employees 44 -
CDP Score - -


420 Lexington Ave Rm 2012
NEW YORK, NY 10170-2099
United States - Map
+1-212-2970010 (Phone)
+1-212-2970019 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company's uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.

Officers and directors

Gary S. Jacob Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 68
Bio & Compensation  - Reuters
Marino Garcia Executive Vice President and Chief Strategy Officer
Bio & Compensation  - Reuters
Patrick H. Griffin M.D. Executive Vice President and Chief medical officer
Age: 60
Bio & Compensation  - Reuters
Bernard F. Denoyer CPA Senior Vice President - Finance, Secretary, IR Contact Officer
Age: 67
Bio & Compensation  - Reuters
Kunwar Shailubhai Ph.D. Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Troy Hamilton Chief Commercial Officer
Bio & Compensation  - Reuters
Thomas H. Adams Jr., Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 67
Bio & Compensation  - Reuters
Timothy Callahan Independent Director
Bio & Compensation  - Reuters
Richard J. Daly Independent Director
Age: 62
Bio & Compensation  - Reuters